<ul>
<li>Portfolio company Maike Biopharma (02335.HK) listed on the Hong Kong main board on June 24 under the 18A regime.     *      IPO sold 58,054,000 H shares at HKD 18.2 each; gross proceeds HKD 1.06 billion; open price HKD 34.02, up 86.92%.     *      Market capitalization topped HKD 11.2 billion on debut; ZheShang Venture Capital funds invested more than CNY 138 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZheShang Venture Capital Co. Ltd. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</li>
</ul>

02335

<p>Maike Biopharmadebuted on the Hong Kong Stock Exchange's main board under the 18A regime, with shares surging 86.92% to HKD 34.02. The IPO raised HKD 1.06 billion by selling 58.05 million H-shares at HKD 18.2 each, achieving a debut market capitalization of HKD 11.2 billion. ZheShang Venture Capital, having invested over CNY 138 million, backed the company.</p>

ZheShang Venture-backed Maike Pharma jumps 86.92% in Hong Kong debut after HKD 1.06 billion IPO